The UMCG website shows YouTube videos. YouTube places cookies if you watch them. Choose ‘Rather not’ if you do not want these cookies. We also place cookies of our own. These help us improve the usability of our website.
More on our cookie policy.
Open label study with oral esketamine for treatment-resistent depression
Research
Major depressive disorder is one of the leading causes of burden of disease worldwide. Depression is highly prevalent and often shows a chronic or recurrent course. Approximately 20 - 30 % of patients do not achieve remission with regular treatment strategies such as antidepressants and psychotherapy.
In this open label study, we provide off-label treatment with oral esketamine to patients who have exhausted all conventional treatment steps according to the Dutch guideline for treatment of depression, including monoamine oxidase inhibitors and electroconvulsive therapy. Oral administration of esketamine might be less invasive, more patient friendly and potentially less costly than alternatives such as intravenous ketamine or intranasal esketamine.
The oral esketamine is administered twice weekly over the course of six weeks, in a liquid formulation. The treatment is provided in an inpatients or day clinic setting, with nurses providing (emotional) support and monitoring the acute effects of esketamine. After an elaborate evaluation after six weeks, optional maintenance treatment is based on shared decision making between the patient and clinician. Three specialized depression treatment centers offer this oral esketamine treatment protocol; the University Center of Psychiatry in Groningen, Pro Persona in Nijmegen and PsyQ / Parnassia Groep in the Hague. Together they collect data on effectiveness and side effects, to increase knowledge on this innovative treatment option.
This researchproject is part of researchgroup Psychedelic Treatment and Mechanisms - University Center of Psychiatrie.
Relevance
How our research benefits to society
This study offers patients who are desperately in need of new treatment options, the opportunity to try esketamine as an antidepressant. Through joint data collection in three treatment centers, the effectiveness, side effects and predictive value of different clinical characteristics can be investigated in a relatively large sample. Furthermore, the patients who enter the longer term maintenance phase are monitored until cessation of the esketamine treatment. This allows research regarding longer term side effects on cognition, live rand kidneys or the development of tolerance.
Contact
University Medical Center Groningen (UMCG)
University Center of Psychiatry (UCP)
PO Box 30.001
9700 RB Groningen
The Netherlands
Visiting address
University Medical Center Groningen (UMCG)
University Center of Psychiatry (UCP)
Hanzeplein 1, Triadegebouw
9713 GZ Groningen